Telix Pharmaceuticals (TLX) Long-Term Investments (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Long-Term Investments for 3 consecutive years, with $37.1 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments rose 1.12% to $37.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.1 million through Dec 2025, up 1.12% year-over-year, with the annual reading at $37.1 million for FY2025, 6.76% up from the prior year.
  • Long-Term Investments for Q4 2025 was $37.1 million at Telix Pharmaceuticals, up from $36.7 million in the prior quarter.
  • The five-year high for Long-Term Investments was $37.1 million in Q4 2025, with the low at $8.0 million in Q4 2023.
  • Average Long-Term Investments over 3 years is $27.3 million, with a median of $36.7 million recorded in 2024.
  • The sharpest move saw Long-Term Investments surged 359.61% in 2024, then increased 1.12% in 2025.
  • Over 3 years, Long-Term Investments stood at $8.0 million in 2023, then surged by 359.61% to $36.7 million in 2024, then increased by 1.12% to $37.1 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $37.1 million, $36.7 million, and $8.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.